Update: IMPALA up and running
Mologen has initiated the Phase III IMPALA study with its lead candidate MGN1703 (TLR9 agonist), as a maintenance therapy after first-line chemotherapy in patients with metastatic colorectal cancer (mCRC). The aim of the 540-patient study is to improve overall survival, the gold standard endpoint for oncology trials. This is an important milestone and initial survival data from the study are projected for H217. We had already assumed a Phase III probability of success for MGN1703 in mCRC at 65%, so our valuation is maintained at €340m, or €20 per share.Mologen is a biotechnology company researching and developing deoxyribonucleic acid (DNA)-based drugs for diseases that require a high degree of medical treatment. Co.'s activities concentrate on creating new and improving existing immunological drugs and therapies to combat cancer and developing vaccines for the prevention and treatment of serious infectious diseases in humans, as well as animals. Two core areas of Co.'s operations are the treatment of cancer and infectious diseases. Co. developed and patented two technologies that allow for the use of DNA as a therapeutic treatment against diseases that were previously incurable or treatable to an unsatisfactory degree.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.